Tinevimbo joined LSTM as a senior research associate in health economics in August 2018. He studied computational and applied mathematics at the University of the Witwatersrand, South Africa. After his PhD he worked as a research fellow at the Respiratory and Meningeal Pathogens Research Unit, University of Witwatersrand and then in 2015 he joined Warwick Clinical Trials Unit, Warwick University as an infectious disease modeller/health economist working mainly on programmes evaluating the impact of childhood pneumococcal vaccines on pneumococcal disease.
Tinevimbo leads the health economics work packages on phase II and III trials assessing the delivery of integrated care for patients with HIV, diabetes and hypertension in sub-Saharan Africa. He also leads a work package on the AMBITION trial that compares single, high dose Ambisome (a liposomal form of amphotericin) treatment to the WHO first-line recommended regimen of a 7-day course of amphotericin B deoxycholate based treatment in avoiding all-cause mortality in HIV-associated cryptococcal meningitis in sub-Saharan Africa.